Structural modification aimed for improving solubility of lead compounds in early phase drug discovery

B Das, ATK Baidya, AT Mathew, AK Yadav… - Bioorganic & Medicinal …, 2022 - Elsevier
Many lead compounds fail to reach clinical trials despite being potent because of low
bioavailability attributed to their insufficient solubility making solubility a primary and crucial …

Recent advances in the synthesis of hydantoins: the state of the art of a valuable scaffold

L Konnert, F Lamaty, J Martinez, E Colacino - Chemical Reviews, 2017 - ACS Publications
The review highlights the hydantoin syntheses presented from the point of view of the
preparation methods. Novel synthetic routes to various hydantoin structures, the advances …

Protein structure prediction with in-cell photo-crosslinking mass spectrometry and deep learning

K Stahl, A Graziadei, T Dau, O Brock… - Nature …, 2023 - nature.com
While AlphaFold2 can predict accurate protein structures from the primary sequence,
challenges remain for proteins that undergo conformational changes or for which few …

Synthesis and antimicrobial activity of some new thiazole, thiophene and pyrazole derivatives containing benzothiazole moiety

S Bondock, W Fadaly, MA Metwally - European journal of medicinal …, 2010 - Elsevier
In an attempt to find a new class of antimicrobial agents, a series of thiazole, thiophene,
pyrazole and other related products containing benzothiazole moiety were prepared via the …

The importance of plasma protein binding in drug discovery

GL Trainor - Expert opinion on drug discovery, 2007 - Taylor & Francis
Plasma protein binding of drugs is a well-recognised phenomena, but it is only recently that
the implications for drug action in vivo have been fully appreciated. Plasma proteins, by …

Hit discovery and hit-to-lead approaches

GM Keserű, GM Makara - Drug discovery today, 2006 - Elsevier
Hit discovery technologies range from traditional high-throughput screening to affinity
selection of large libraries, fragment-based techniques and computer-aided de novo design …

Cyclin dependent kinase 9 inhibitors for cancer therapy: miniperspective

YA Sonawane, MA Taylor, JV Napoleon… - Journal of medicinal …, 2016 - ACS Publications
Cyclin dependent kinase (CDK) inhibitors have been the topic of intense research for nearly
2 decades due to their widely varied and critical functions within the cell. Recently CDK9 has …

Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors

I Collins, MD Garrett - Current opinion in pharmacology, 2005 - Elsevier
The cyclin-dependent kinase (CDK) family of serine/threonine kinases regulate progression
through each stage of the cell division cycle and as such are major targets for deregulation …

4-Arylazo-3,5-diamino-1H-pyrazole CDK Inhibitors:  SAR Study, Crystal Structure in Complex with CDK2, Selectivity, and Cellular Effects

V Kryštof, P Cankař, I Fryšová, J Slouka… - Journal of medicinal …, 2006 - ACS Publications
In a routine screening of our small-molecule compound collection we recently identified 4-
arylazo-3, 5-diamino-1 H-pyrazoles as a novel group of ATP antagonists with moderate …

Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors

GS Hassan, HH Georgey, EZ Mohammed… - European Journal of …, 2021 - Elsevier
Novel series of diphenyl-1H-pyrazoles (4a-g) and pyrazolo [3, 4-b] pyridines (5a-g and 7a-i)
were synthesized and evaluated for their antiproliferative activity against breast cancer cell …